Effects of Three Strong Statins (Atorvastatin, Pitavastatin, and Rosuvastatin) on Serum Uric Acid Levels in Dyslipidemic Patients

  title={Effects of Three Strong Statins (Atorvastatin, Pitavastatin, and Rosuvastatin) on Serum Uric Acid Levels in Dyslipidemic Patients},
  author={Nobuyuki Ogata and Shin Fujimori and Yoko Oka and Kiyoko Kaneko},
  journal={Nucleosides, Nucleotides \& Nucleic Acids},
  pages={321 - 324}
We have retrospectively investigated the effects of three strong statins, atorvastatin, pitavastatin, and rosuvastatin, on serum uric acid (SUA) levels. SUA levels after a few months of statin treatment were compared with those before treatment in 150 outpatients with dyslipidemia. In the atorvastatin (n = 62) and rosuvastatin (n = 45) groups, the SUA levels were reduced by 6.5% (p < 0.0001) and 3.6% (p = 0.03) respectively, but in the pitavastatin group (n = 43), the SUA level increased by 3.7… 
Effects of Statin Monotherapy Versus Statin Plus Ezetimibe Combination on Serum Uric Acid Levels
A significant reduction in serum uric acid levels was seen in all treatment groups and correlated with the increase in fractional excretion of Uric acid and baseline uric Acid levels.
Comparative study of efficacy and safety of omega 3 fatty acids and fenofibrate with background atorvastatin therapy in patients of atherogenic dyslipidaemia
Dyslipidemia appears to be widely prevalent in India and migrant Asian Indians, tendency to have higher TGs and lower HDL-C levels due to their less physical activity and consumption of carbohydrate and fat rich diet, and is often observed in patients with metabolic syndrome, obesity, insulin resistance and type 2 diabetes mellitus.
Effect of Lovastatin Therapy and Withdrawal on Serum Uric Acid Level in People With Type 2 Diabetic Nephropathy
There is no correlation between the anti-lipidemic and anti-inflammatory effects of lovastatin and its effect on serum UA in people with type 2 diabetic nephropathy.
Effect of Ezetimibe on LDL-C Lowering and Atherogenic Lipoprotein Profiles in Type 2 Diabetic Patients Poorly Controlled by Statins
Ezetimibe added to high-potency statin was more effective than the intensified-dose statin (20 mg of atorvastatin or 2 mg of pitavastatin) treatment not only in helping T2DM patients attain more LDL-C reduction, but also in improving their atherogenic lipid profiles, including their levels of sd-LDL-C and RLP-C.
Effects of statins on serum polyunsaturated fatty acids
There was an inconsistency of the results between the previous study using low-potency statins and the study using high-potencies statins, and further studies are necessary to clarify whether the inconsistency results from the extent of LDL cholesterol lowering or the potency of statins.
Determinants of Blood Uric Acid Levels in a Dyslipidemic Arab Population
The data showed that hyperuricemia is common in dyslipidemic patients in Kuwait, where its important determinants are male sex, obesity, diabetes and statin treatment.
Impact of Statin Therapy on Plasma Uric Acid Concentrations: A Systematic Review and Meta-Analysis
The present meta-analysis suggested a significant reduction in plasma uric acid levels following statin therapy; however, this does not seem to be a class effect as subgroup analysis revealed asignificant reduction with atorvastatin and simvastati only, and not with pravastatinand rosuvastasin.
The Association of Serum Uric Acid Level With Coronary Collateral Circulation Should Be Interpreted Together With Renal Function and Cardiovascular Medications in Stable Coronary Artery Disease
Uysal et al showed that higher SUA levels were associated with poor CCC in stable CAD, but these results should be interpreted with some limitations.
Prospective study of statin use and risk of Parkinson disease.
It was found that regular use of statins was associated with a modest reduction in PD risk, and the possibility that some statins may reduce PD risk deserves further consideration.
Should our approach to diuretic using in patients with gout change?
There is a need for prospective well-designed studies about the effects of diuretic use on the necessary doses of ULDs to achieve the targeted SU level and the results of this study, which can change clinical practice, should be interpreted with caution.


Treating to target patients with primary hyperlipidaemia:comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study)
RSV and ATV were equally efficacious in achieving LDL‐C treatment goals in patients with primary hyperlipidaemia at the initial dose and following dose titration.
Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study.
Data suggest that SUA level is an independent predictor of CHD recurrent events, thus offsetting an additional factor associated with CHD risk.
Effects of short-term treatment of hyperlipidemia on coronary vasodilator function and myocardial perfusion in regions having substantial impairment of baseline dilator reverse.
The mechanism involves enhanced, flow-mediated dilation of stenotic epicardial conduit vessels and may account at least in part for the efficacy of lipid lowering in secondary prevention trials and in reducing ischemic episodes in ambulatory patients.
Treating to target patients with primary hyperlipidemia:comparison of 324 N
  • Ogata et al. the effects of ATOrvastatin and ROSuvastatin (the ATOROS study). Curr. Med. Res. Opin. 2006,
  • 2006
Uric acid and cardiovascular risk.